Mercer Global Advisors
BOLT icon

Mercer Global Advisors’s Bolt Biotherapeutics BOLT Stock Holding History

Mercer Global Advisors’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12K Buy
+292
New +$1.37K ﹤0.01% 5720

Other funds holding BOLT

TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $508M AUM 163.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Mercer Global Advisors's BOLT Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Bolt Biotherapeutics (BOLT) in Q2 2026: 292 shares worth $1.12K. The stake represents ﹤0.01% of the portfolio and ranks #5720 among its holdings.

11 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

  • Mercer Global Advisors held 292 shares of Bolt Biotherapeutics worth $1.12K as of Q2 2026.
  • Bolt Biotherapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Bolt Biotherapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5720 holding.
  • 11 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.